-

Diality Receives FDA 510(k) Clearance for Its Moda-flx Hemodialysis System

Patient-inspired technology designed to provide ease of use and mobility for dialysis care

IRVINE, Calif.--(BUSINESS WIRE)--Diality, a medical device company developing a smart, flexible hemodialysis platform, today announced that it has secured 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its Moda-flx Hemodialysis System™.

“Receiving 510(k) clinical clearance for Moda-flx is an incredible milestone in our mission of developing solutions to improve lives impacted by kidney disease,” said Osman Khawar, M.D., CEO of Diality. “We believe this platform will represent a new paradigm in the treatment of kidney disease and will help reduce the burden of care for all kidney care stakeholders.”

The Moda-flx Hemodialysis System is designed to empower kidney care professionals with a wide range of variable flow rate ranges, integrated reverse osmosis water filtration, and an intuitive, easy-to-use graphical user interface. The Moda-flx Hemodialysis System provides clinicians the flexibility to easily customize each hemodialysis experience according to patient needs in one integrated system. The platform’s compact footprint and mobility enable integration and transportation within dialysis care settings.

“Dialysis is an area of medicine long overdue for meaningful innovation,” said Dr. Allen R. Nissenson, board member at Diality. “The Moda-flx Hemodialysis System is a huge leap forward and incorporates the right mix of clinical, technical and ease-of-use characteristics to help dialysis providers thrive in today’s challenging environment. I envision Moda-flx will create value for patients and providers across multiple care settings where dialysis is performed.”

The Moda-flx Hemodialysis System is indicated for use in patients with acute and/or chronic renal failure, with or without ultrafiltration, in an acute, post-acute, or chronic care facility. Treatments must be administered under a physician’s prescription, by a trained person who is considered competent in the use of the device. Treatment types available include: Intermittent Hemodialysis (IHD), Sustained Low Efficiency Dialysis (SLED/SLEDD), and Prolonged Intermittent Renal Replacement Therapy (PIRRT).

About Diality

Diality is a medical device company focused on developing solutions to improve lives impacted by kidney disease. The Moda-flx Hemodialysis System is a user-friendly, mobile, and connected hemodialysis platform designed to maximize clinical flexibility by combining prescription capabilities of in-center systems with the ease-of-use of next generation hemodialysis devices. Moda-flx Hemodialysis system obtained U.S. FDA clearance in August 2024. Please visit www.diality.com or find us on LinkedIn to learn more about Diality and The Moda-flx Hemodialysis System™.

Diality


Release Versions

Social Media Profiles
More News From Diality

Diality Announces Three Poster Presentations During The American Society of Nephrology (ASN) Kidney Week 2025

IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc. today announced that three posters highlighting new data from the first clinical use of the Moda-flx™ Hemodialysis System will be presented during the American Society of Nephrology’s Kidney Week 2025 in Houston, Texas. “Real-World Urea Clearance and Adequacy with the Moda-flx Hemodialysis System” proves the system’s ability to leverage 600mL/min dialysate flow rate to achieve weekly clearance and ultrafiltration targets from the standard three hemo...

Diality Announces First Patient Treated in Moda-flx Home IDE PRESCRIBE Diality Clinical Trial

IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced the first patient treatment in its PRESCRIBE Diality Home Hemodialysis Clinical Trial in partnership with aQua Research Institute and aQua Dialysis in Houston, Texas. Diality is conducting the PRESCRIBE Diality trial under an Investigational Device Exemption (IDE) to evaluate a home use indication for the Moda-flx Hemodialysis System. The Moda-flx Hemodia...

Diality Names Dr. Chris Springer to Board of Directors

IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc., a medical device company that has developed the Moda-flx Hemodialysis System™, today announced the addition of Dr. Chris Springer to its board of directors. Dr. Springer brings 30 years of commercial and strategic experience in the pharmaceutical and biotech industries to Diality. As Chief Strategy Officer for Vifor Pharma, he created a joint renal-drug company between Vifor Pharmaceuticals and Fresenius Medical Care as well as oversaw a series of...
Back to Newsroom